Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC(TM) Study Evaluating Trappsol® Cyclo(TM) for the Treatment of Niemann-Pick Disease Type C

Stock Information for Rafael Holdings Inc. Class B

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Rafael Holdings Inc. Class B

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
Rafael Holdings Announces Patent Licensing Agreement with MIT for "Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease"
Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results
Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results
Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors
Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC(TM) Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old
Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.